🇺🇸 Ipilimumab and nivolumab in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Disease Progression — 1 report (100%)
Other Oncology approved in United States
Frequently asked questions
Is Ipilimumab and nivolumab approved in United States?
Ipilimumab and nivolumab does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ipilimumab and nivolumab in United States?
Leiden University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.